FDA Grants Fast Track Designation to Perspective Therapeutics' PSV359

Key Facts

1The U.S. FDA granted Fast Track Designation for PSV359 for the treatment of FAP-positive solitary fibrous tumors.

The U.S. FDA granted Fast Track Designation for PSV359 for the treatment of FAP-positive solitary fibrous tumors. GlobeNewswire reported that Perspective Therapeutics announced its radiopharmaceutical candidate, [212Pb]PSV359, received the designation for treating advanced or metastatic tumors to accelerate the development and review of drugs filling unmet medical needs.

CATX closed at $2.46 on October 7, 2026, with a session high of $2.51 and a low of $2.32. The designation is intended to expedite the pathway for drugs treating serious conditions, supporting the company's strategy of engineering targeted radiopharmaceutical therapies based on the alpha-generating isotope 212Pb to optimize therapeutic outcomes in oncology.